Back to top
more

Novartis (NVS)

(Delayed Data from NYSE)

$106.45 USD

106.45
1,174,113

-0.63 (-0.59%)

Updated Nov 8, 2024 04:00 PM ET

After-Market: $107.09 +0.64 (0.60%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value C Growth C Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 23% (57 out of 250)

Industry: Large Cap Pharmaceuticals

Zacks News

Teva Q2 Earnings Lag, '17 View & Dividend Cut, Stock Slumps

Teva Pharmaceutical Industries Limited's (TEVA) Q2 earnings and missed expectations. It also slashed its 2017 earnings and sales outlook and cut its dividend by 75%.

    Conatus (CNAT) Q2 Loss Narrows Y/Y, Revenues Beat Estimates

    Conatus (CNAT) reports wider-than-expected loss in Q2. However, revenue beat estimates, courtesy higher collaboration benefits.

      Aduro (ADRO) Q2 Loss Narrower than Expected, Revenues Top

      Aduro (ADRO) incurs loss in Q2 but revenues beat estimates. However, the same declines year over year, courtesy a milestone payment from the year-ago quarter.

        Incyte (INCY) Q2 Loss Wider than Expected, Jakafi Strong

        Incyte (INCY) reported a wider-than-expected loss in the second quarter but revenues beat expectations.

          Can Ligand (LGND) Pull a Surprise This Earnings Season?

          Milestone payment on Baxdela's approval in the U.S. leveraging Ligand's (LGND) Captisol formulation technology and partnerships with leading healthcare companies, might drive the company in Q2.

            Intercept (ICPT) Posts Narrower-than-Expected Loss in Q2

            Intercept Pharmaceuticals (ICPT) reported a narrower-than-expected loss in Q2 on the back of higher Ocaliva sales.

              Drug Stocks Q2 Earnings Releases on Aug 1: PFE, AERI & INCY

              The Medical sector has carried on the momentum of its first quarter performance so far this earnings season but lagged the overall market.

                Roche's (RHHBY) Sales Grow Y/Y in 1H17 on New Drug Launches

                Roche Holdings (RHHBY) delivered an impressive performance in 1H17 driven by new drug launches.

                  Ophthotech (OPHT) Q2 Loss Narrows, Focus Shifts to Zimura

                  Ophthotech Corporation (OPHT) reported narrower-than-expected loss in the second quarter and also beat sales expectations.

                    What's in Store for Conatus (CNAT) this Earnings Season?

                    Conatus' (CNAT) aim to progress with its lead candidate emricasan might boost the stock in Q2 results, although the company's current portfolio shows no approved product and revenue generation.

                      Amgen (AMGN) Stock Falls Despite Q2 Earnings & Sales Beat

                      Amgen Inc. (AMGN) beat estimates on both earnings & sales in Q2. While Amgen slightly tightened the sales guidance, it raised the earnings outlook backed by its strong performance in the first half.

                        Biotech Stocks Jul27 Q2 Earnings Roster: BMY, CELG & ALXN

                        Bristol-Myers Squibb Company (BMY), Celgene (CELG) and Alexion Pharma (ALXN) are set to report second-quarter results on Jul 27.

                          Drug Stocks Q2 Earnings Releases on Jul 26: GILD, VRTX, GSK

                          We have three pharma giants that are set to report second-quarter results on Jul 26. Let's see how things are shaping up for this quarter.

                            Swarup Gupta headshot

                            Foreign Stock Roundup: ABB, Novartis Beat on Earnings

                            Global markets were weighed down by comments from the ECB and Bank of Japan even as bullish GDP data emerged from China this week

                              Big Pharma Q2 Earnings Releases on Jul 25: LLY, BIIB, AMGN

                              Three pharma giants are set to report second-quarter results on Jul 25. Let's see how things are shaping up for this quarter.

                                Amgen (AMGN) to Report Q2 Earnings: What's in the Cards?

                                While Amgen, Inc.'s (AMGN) growth drugs like Prolia & Xgeva might continue to do well. Biosimilar competition and slowdown in sales of mature products can put pressure on sales growth.

                                  Puma's (PBYI) Breast Cancer Drug Neratinib Gets FDA Approval

                                  Puma Biotechnology, Inc's (PBYI) lead breast cancer candidate neratinib is approved by FDA and is set to be commercially available in September under the brand name, Nerlynx.

                                    Ligand Signs Agreement with Amgen, Grants Rights to Captisol

                                    Ligand Pharmaceuticals Incorporated (LGND) announced that it has signed a commercial license and supply agreement with Amgen Inc. granting exclusive worldwide rights to use Ligand's Captisol technology for the development of AMG 330

                                      Novartis Tops Q2 Earnings, Sandoz Faces Pricing Pressure

                                      Novartis AG (NVS) reported second-quarter 2017 core earnings of $1.22 per share, beating the Zacks Consensus Estimate of $1.16 but the recorded figure was a penny lower than the year-ago figure of $1.23.

                                        Arpita Dutt headshot

                                        5 CAR-T Stocks in Focus as NVS Drug Wins FDA Advisory Panel Vote

                                        It's time to look at these 5 CAR-T stocks given the interest generated by a positive FDA advisory panel vote for Novartis' (NVS) experimental CAR-T treatment.

                                          Arpita Dutt headshot

                                          4 Sell-Ranked Drug Stocks to Avoid Ahead of Q2 Earnings

                                          Here is a look at four drug stocks including Anika (ANIK) with a Sell Rank and negative earnings ESP that should be avoided ahead of earnings.

                                            J&J (JNJ) Gets FDA Nod for Psoriasis Drug -- Guselkumab

                                            Johnson & Johnson (JNJ), a healthcare bellwether, announced that the FDA has approved its pipeline candidate guselkumab for the treatment of moderate-to-severe plaque psoriasis. The drug will be marketed by the trade name of Tremfya.

                                              Can Novartis (NVS) Spring a Surprise This Earnings Season?

                                              Swiss pharmaceutical company Novartis AG (NVS) is scheduled to report second-quarter 2017 results on Jul 18.

                                                Novartis CAR-T Therapy Drug Recommended by FDA Panel

                                                Novartis AG (NVS) announced that the FDA Oncologic Drugs Advisory Committee (ODAC) has unanimously (10-0) recommended the approval of immunocellular therapy candidate CTL019 (tisagenlecleucel).

                                                  Can ImmunoGen's Lead Pipeline Cancer Candidate Boost Growth?

                                                  On Jul 12, 2017, we issued an updated report on ImmunoGen, Inc. (IMGN).